MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2023.12.048

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.

Silverberg Jonathan I, Kirsner Robert S, Margolis David J, Tharp Michael, Myers Daniela E, Annis Karen, Graham Daniela, Zang Chuanbo, Vlahos Bonnie L, Sanders Paul

Рандомизированное исследованиеКлиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Crisaborole ointment, 2%, is a nonsteroidal topical phosphodiesterase 4 inhibitor approved for the treatment of mild-to-moderate atopic dermatitis.

OBJECTIVE

To evaluate the efficacy and safety of crisaborole in stasis dermatitis (SD).

METHODS

In this randomized, double-blind, vehicle-controlled, decentralized phase 2a study (NCT04091087), 65 participants aged ≥45 years with SD without active ulceration received crisaborole or vehicle (1:1) twice-daily for 6 weeks. The primary end point was percentage change from baseline in total sign score at week 6 based on in-person assessment.

RESULTS

Crisaborole-treated participants had significantly reduced total sign score from baseline versus vehicle based on in-person (nondermatologist) assessment (-32.4% vs -18.1%, P = .0299) and central reader (dermatologists) assessment of photographs (-52.5% vs -10.3%, P = .0004). Efficacy according to success and improvement per Investigator's Global Assessment score and lesional percentage body surface area reached statistical significance based on central reader but not in-person assessments. Skin and subcutaneous tissue disorders were common all-causality treatment-emergent adverse events with crisaborole.

LIMITATIONS: Small sample size and short treatment duration were key limitations. In-person assessment was not conducted by dermatologists.

CONCLUSION

Crisaborole improved signs and symptoms of SD and was well tolerated. Central reader assessment represents a promising approach for siteless clinical research.

Для цитирования: Silverberg Jonathan I, Kirsner Robert S, Margolis David J, Tharp Michael, Myers Daniela E, Annis Karen, Graham Daniela, Zang Chuanbo, Vlahos Bonnie L, Sanders Paul. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2023.12.048.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.